When people hear “cannabis and depression” they usually go one of two ways.
Either it’s framed like cannabis is a cure all or it’s dismissed as automatically harmful. Neither is responsible and neither helps patients who are genuinely struggling, especially folks living with treatment resistant depression.
A new paper from the UK Medical Cannabis Registry adds an important piece to the conversation. It’s not a randomized clinical trial, so it can’t prove cause and effect. But it does give us longer-term, real-world patient reported data over two years, which is still valuable when handled carefully.
What did the researchers do?
Researchers analyzed data from the UK Medical Cannabis Registry and focused on patients with depression who were prescribed cannabis based medicinal products (CBMPs) as part of their care.
They tracked several standard patients reported outcome measures over time, including:
- PHQ 9 (depression severity)
- GAD 7 (anxiety severity)
- Sleep quality (Single Item Sleep Quality Scale)
- Health related quality of life (EQ 5D 5L)
- Patient Global Impression of Change (PGIC)
Assessments were collected at baseline and at 1, 3, 6, 12, 18 and 24 months.
Who was in the study?
Out of 34,563 registry patients at the timepoint used for the analysis, 698 patients met criteria and were included.
Also worth noting at baseline, about half of these patients reported severe anxiety and anxiety severity was strongly correlated with depression severity. That matters because anxiety and depression often travel together and changes in one can influence the other.
What were the results?
After starting CBMP treatment, patients showed improvements across depression scores, anxiety scores, sleep quality and health related quality of life at all measured follow ups compared with baseline.
Two points stood out:
- Most of the improvement happened early
Changes were largest in the first 3 months, then generally persisted through 24 months. - People with more severe symptoms at baseline tended to improve more
Higher baseline symptom severity predicted greater improvement, which is a pattern we see in other areas of medicine too, but it can also reflect regression to the mean.
What about side effects?
In this analysis, 9.03% of patients reported at least one adverse event, and most were mild to moderate.
That’s encouraging, but it’s not the same as saying cannabis is “safe for everyone,” especially when product types, THC exposure, and individual vulnerability vary a lot.
The most important part: what this study does not prove
This was a registry based observational case series, not a randomized controlled trial. The authors are explicit that no causal relationship can be established from this design.
That means we should be careful about overreading it. A few reasons:
- No randomization and no placebo control
- People in a medical cannabis registry may differ from the general population
- Other treatment changes over 2 years can influence outcomes
- Patient reported outcomes are meaningful, but they are still self-reported
So, the honest takeaway is not “cannabis treats treatment resistant depression.” The honest takeaway is:
In this cohort, starting prescribed CBMPs was associated with sustained improvements in patient reported depression, anxiety, sleep, and quality of life and the signal was strongest early on.
My educator’s takeaway
If you care about evidence, this study supports a middle ground:
- It’s a meaningful signal that deserves follow up
- It doesn’t justify sweeping claims
- It strengthens the case for better trials that are stratified by product composition, comorbidities, and long-term safety outcomes
The authors themselves call for further randomized trials to confirm efficacy and clarify long term safety.
Practical, responsible guidance
If someone is considering cannabis within a mental health plan:
- Do not treat this as a replacement for therapy, crisis care, or prescribed medications
- Work with a qualified clinician, especially if there is a history of bipolar disorder, psychosis, substance use disorder, or severe anxiety
- Be cautious with high THC products, especially early on
- Avoid driving or safety sensitive tasks when impaired
And if you or someone you love is in crisis, please seek immediate professional help or local emergency resources.
If you want this kind of research translated into real world language, follow Herbal IQ Education. I break down what the data actually says, what it doesn’t, and the questions we should be asking next.
If you want, I’ll do a follow up post on:
“What treatment resistant depression means, and why study design matters so much in cannabis research.”
Comment “TRD” and I’ll write it.
References
- NORML news summary of the study and context.
- Lillywhite E, Erridge S, et al. UK Medical Cannabis Registry: A two year case series of clinical outcomes in depression. Journal of Affective Disorders (open access).
Disclaimer
Educational content only. Not medical advice. This post does not claim that cannabis prevents, treats, or cures depression or any disease. Individual responses and risks vary, and cannabis may worsen symptoms for some people. Follow local laws and consult a licensed clinician for personalized guidance.
#HerbalIQ #CannabisEducation #MentalHealthEducation #DepressionAwareness #TreatmentResistantDepression #EvidenceBased #PublicHealth #CannabinoidScience #HealthLiteracy #ScienceCommunication #HarmReduction #PatientReportedOutcomes
